You will have to skip most steps to optimize production and recovery but it is doable. I know there are multiple companies pursuing this type of work. The biggest problem will be the actual efficacy of the monoclonal antibodies. I remember there was pretty good data with SARS before the lack of infections killed most of the projects but that doesn’t guarantee efficacy. Everyone is moving as fast as possible, making reasonable guesses but again lots of steps are being skipped